Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CAR-T for ALL: bridging options and choices

Karlo Perica • 1 Jun 2019
ASCO 2019
Acute Lymphoblastic Leukemia

Karlo Perica, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, explains the options clinicians have when choosing bridging options for acute lymphoblastic leukemia (ALL) patients undergoing CAR T-cell therapy, and how decisions are made. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Karlo Perica

3:12
CAR-T for ALL: the impact of bridging therapy
Karlo Perica • 1 Jun 2019
0:59
Characterizing bridging strategies for CAR T-cell therapy
Karlo Perica • 1 Jun 2019

Related Videos

1:03
Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL
Elias Jabbour • 10 Dec 2023
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
2:36
A CD38-targeting bispecific antibody in the treatment of R/R T-ALL
Guru Subramanian Guru Murthy • 10 Dec 2023
3:13
Targeting CD38 with a bispecific antibody to treat R/R AML: a Phase I trial
Guru Subramanian Guru Murthy • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals